CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets
Wednesday October 11, 7:00 am ET
PALO ALTO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) announced today that it has sent Solvay Pharmaceuticals, Inc. a notice of termination under the companies' co-promotion agreement for ACEON® (perindopril erbumine) Tablets. Over the next several weeks, CV Therapeutics will conclude its promotion of ACEON.
ADVERTISEMENT
There are no financial commitments for either company related to the termination of the co-promotion agreement. CV Therapeutics does not expect to recognize further revenues from ACEON.
"We are excited to focus our promotional efforts on Ranexa, as we continue to see growing interest in the cardiology community," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved product, Ranexa® (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies and CVT-6883, which is being developed as a potential treatment for asthma and other conditions. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use. |
